---
document_datetime: 2026-01-27 10:17:48
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mvasi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: mvasi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.7845596
conversion_datetime: 2026-01-29 12:24:14.476265
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MVASI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0032/G            | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 06/01/2025                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                     |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1743           | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                           | 28/06/2024 |            | Annex II    |                                                                                                                                                                                                                                                                     |
| IB/0029/G         | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 11/07/2023 | n/a        |             |                                                                                                                                                                                                                                                                     |
| PSUSA/403/2 02202 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                  | 13/10/2022 | 20/12/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/403/202202.                                                                                                                            |
| R/0025            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                    | 21/07/2022 | 21/09/2022 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of MVASI in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0027           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                           | 07/09/2022 | n/a        |             |                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0028           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                 | 12/07/2022   | 21/09/2022   | SmPC and PL   | Update of section 4.2 and 6.6 of the SmPC and section 3 of the package leaflet by adding 'Do not shake the vial'. The MAH also took this opportunity to make a small editorial correction to the contact details of the local representative in DE and aligned the annexes with the currently approved annexes of the reference product.   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/403/2 02102 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                    | 30/09/2021   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                          |
| IB/0024           | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                   | 06/09/2021   | n/a          |               |                                                                                                                                                                                                                                                                                                                                            |
| IB/0023           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                 | 09/07/2021   | 08/07/2022   | SmPC and PL   |                                                                                                                                                                                                                                                                                                                                            |
| WS/2026           | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method | 08/07/2021   | n/a          |               |                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0020           | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                          | 11/05/2021   | n/a        |                       |                                   |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------|
| II/0017           | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS             | 04/03/2021   | n/a        |                       |                                   |
| IB/0019           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 26/02/2021   | 21/04/2021 | SmPC, Annex II and PL |                                   |
| IB/0018           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 21/12/2020   | n/a        |                       |                                   |
| PSUSA/403/2 02002 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                    | 01/10/2020   | n/a        |                       | PRAC Recommendation - maintenance |
| IB/0016/G         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO         | 05/08/2020   | 15/09/2020 | SmPC and PL           |                                   |

<div style=\"page-break-after: always\"></div>

|           | required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        | new additional data is   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------|
| IB/0015   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                              | 21/07/2020 | 15/09/2020 | SmPC and PL            |                          |
|           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                 | 22/06/2020 | n/a        |                        | IAIN/0014                |
| IA/0012   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                      | 11/05/2020 | 15/09/2020 | Annex II and PL        |                          |
| T/0011    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                | 10/03/2020 | 01/04/2020 | SmPC, Labelling and PL |                          |
|           | This was an application for a group of variations. C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication                                                                 | 07/01/2020 | 13/02/2020 | SmPC and PL            | IB/0010/G                |
| IAIN/0009 | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                     | 30/10/2019 | 13/02/2020 | SmPC and PL            |                          |

<div style=\"page-break-after: always\"></div>

|                   | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |          |                                   |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| II/0008           | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                        | 12/09/2019 | n/a        |          |                                   |
| PSUSA/403/2 01902 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/09/2019 | n/a        |          | PRAC Recommendation - maintenance |
| N/0006            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/04/2019 | 13/02/2020 | PL       |                                   |
| II/0005/G         | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 29/11/2018 | 06/02/2019 | Annex II |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/403/2 01802   | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                              | 06/09/2018   | n/a        |                 | PRAC Recommendation - maintenance   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------|
| IG/0946             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 04/06/2018   | 06/02/2019 | PL              |                                     |
| IAIN/0001           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 12/02/2018   | 06/02/2019 | Annex II and PL |                                     |